DEA Targets Three New Mitragynine Compounds for Schedule I
Published Date: 7/6/2026
Proposed Rule
Summary
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Possession Becomes a Schedule I Offense
If you possess mitragynine pseudoindoxyl, MGM-15, or MGM-16 after the temporary order is published, you will be subject to Schedule I rules and the CSA's civil and criminal penalties. The temporary order will take effect on the date it is published in the Federal Register (to be published on or after August 5, 2026) and impose schedule I controls.
Researchers Face Schedule I Requirements
If you conduct research, instructional activities, or chemical analysis with mitragynine pseudoindoxyl, MGM-15, or MGM-16, those activities will be subject to Schedule I regulatory controls and associated administrative requirements and sanctions once the temporary order is published. The temporary order will take effect on its publication date (on or after August 5, 2026).
Retailers and Vendors Lose Legal Market Access
Retailers, online vendors, vape shops, gas stations, and other sellers of products containing these chemicals will be subject to Schedule I prohibitions on manufacture and distribution when the temporary order is published. Selling or distributing these substances will trigger the CSA's criminal and civil sanctions.
Temporary Scheduling Period Set (2 + 1 Years)
The temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I will remain in effect for two years from the order's publication date, with a possible one-year extension if regular scheduling proceedings are initiated. The DEA intends to publish the temporary scheduling order on or after August 5, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
Previous / Next Documents
Previous: 2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
Next: 2026-13586 — Registering NFA Firearms That Fall Out of Government Contract
If you make special firearms for the U.S. Government and your contract ends, you’ll now have a new way to register those guns even if you missed the usual deadline. This change helps manufacturers avoid penalties and keeps everything clear and fair. Comments on this proposal are open until September 4, 2026, so don’t miss your chance to weigh in!